Semaglutide: forty questions, forty sourced answers

A once-weekly GLP-1 receptor agonist sold as Wegovy (weight management), Ozempic (type 2 diabetes), and daily-oral Rybelsus.

STEP 1 averaged about 14.9% of body weight over 68 weeks at 2.4 mg — with wide individual spread around that mean.

Same molecule, different labels and dose ceilings: Wegovy is approved for weight management up to 2.4 mg; Ozempic for diabetes — the distinction drives insurance, not biology.

0.25 mg weekly for four weeks, then 0.5, 1.0, 1.7, and a 2.4 mg maintenance target as tolerated, per the Wegovy label.

Take it within five days; beyond that, skip and resume on schedule — and if more than two weeks lapse, ask your prescriber about re-titration.

Half-life is about a week, so weekly dosing holds steady levels and drug effects persist for weeks after stopping.

The class GI set — nausea, vomiting, diarrhea, constipation — mostly mild-to-moderate and concentrated around dose escalations.

Smaller, slower, lower-fat meals, fluids, and not lying down after eating; clinicians can hold a dose step or add anti-nausea medication when needed.

Both are reported — slowed emptying keeps food and gas around longer; meal-pattern changes are first-line, persistent reflux merits a clinician.

Boxed thyroid C-cell warning (rodent findings), plus pancreatitis, gallbladder disease, severe GI events, and hypoglycemia with insulin or sulfonylureas.

Personal or family history of medullary thyroid carcinoma or MEN2, prior serious reaction to it, and pregnancy.

Yes — the Wegovy label advises discontinuing at least two months before a planned pregnancy.

Anesthesia guidance has advised holding weekly GLP-1s about a week before sedated procedures; disclose it to every surgical team and follow their protocol.

No pill-specific warning like tirzepatide's; severe vomiting from any cause can still compromise oral contraception.

No listed interaction, but a slowed stomach changes how alcohol lands, and diabetes co-medication adds hypoglycemia risk — moderation and awareness.

In people with cardiovascular disease and overweight/obesity (without diabetes), semaglutide 2.4 mg cut major cardiovascular events — the result that reshaped coverage arguments.

In type 2 diabetes with chronic kidney disease, semaglutide slowed kidney-disease progression and improved outcomes — relevant context for comorbid patients.

At approved doses it's a diabetes product with more modest weight effects; its absorption ritual — empty stomach, ≤4 oz water, wait 30 minutes — is non-negotiable chemistry.

No — approved oral delivery requires the Rybelsus absorption-enhancer system; compounded oral or sublingual formats have no established absorption record.

Semaglutide sodium or acetate are chemically different substances the FDA has specifically flagged; their presence marks a seller to avoid.

Only through 503A patient-specific prescriptions with documented clinical rationale — same post-shortage framework as tirzepatide.

Same intended active ingredient, different unreviewed product — no FDA check on safety, efficacy, or consistency.

Wegovy self-pay via NovoCare runs about $499/month; the cheapest audited compounded figures in our field are $119/month standard and $110 microdose on 12-month plans.

Older molecule, more supply and competition, single-agonist economics — the audited gap in our field is $240/year, which the head-to-head efficacy data prices.

SURMOUNT-5 favors tirzepatide on average loss (≈20.2% vs 13.7%); semaglutide answers with price, longer history, and outcome-trial data — a clinician call your budget also votes in.

The STEP-1 extension's average: about two-thirds of lost weight regained within a year off, with cardiometabolic gains largely reverting — plan maintenance before stopping.

No formal protocol; stepping down the dose ladder under clinician guidance is the common approach to find where appetite control holds.

Same verdict as tirzepatide: no trial of the practice exists; lower studied doses do less but something, and sub-studied dosing is unproven by definition.

Lean mass falls with any major loss; resistance training plus ~1.2–1.6 g/kg/day protein is the standard counter.

Trials didn't show a depression signal, and regulators reviewing post-market reports have not confirmed causality; new mood changes still deserve a clinician conversation.

Commonly combined in diabetes care; no direct interaction, with GI overlap the practical note.

Slowed emptying can alter levothyroxine absorption; keep consistent timing and let your prescriber monitor thyroid labs.

Refrigerated at 36–46°F; in-use room-temperature windows differ by product and format — check your specific label rather than borrowing a friend's rule.

Never — pen-sharing risks bloodborne infection even with needle changes, and it's a fast way to dose-error territory.

Know your vial's mg/mL and convert to units before the first draw; concentration varies by pharmacy and unit errors are the classic overdose story.

Audited: $119/month standard and $110/month microdose (evidence caveat attached), both dose-proof, all-in, on 12-month plans.

No — berberine's trial effects are a fraction of semaglutide's; 'nature's Ozempic' is marketing, not pharmacology.

Appetite changes often within weeks; the average curve builds across months of titration rather than arriving at week one.

Yes — usually for cost or tolerability; clinicians map doses rather than starting at 2.4 mg, and expectations should track the head-to-head data.

'What will month seven cost at maintenance dose, in writing?' — the answer reveals the entire pricing model.